At Supplement Regulation Table, Industry And FDA Target Dealing Out 'Quick Buck' Players
This article was originally published in The Rose Sheet
Executive Summary
FDA's ODSP, says Director Steven Tave, found "how much there is in common between what our goals are at FDA and what your goals are in the industry." Trade group executives suggest changes both for the industry and FDA, though none expect noncompliant firms to fall into line short of being forced off the market.